Literature DB >> 10755461

Nutritional supplementation in Down syndrome: theoretical considerations and current status.

C Ani1, S Grantham-McGregor, D Muller.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10755461     DOI： 10.1017/s0012162200000359

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN： 0012-1622            Impact factor:   5.449


× No keyword cloud information.
  4 in total

1.  Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study.

Authors:  Cindy K Blair; Michelle Roesler; Yang Xie; Alan S Gamis; Andrew F Olshan; Nyla A Heerema; Leslie L Robison; Julie A Ross
Journal:  Paediatr Perinat Epidemiol       Date:  2008-05       Impact factor: 3.980

2.  Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.

Authors:  Adviye A Tolun; Peter M Scarbrough; Haoyue Zhang; Jane-Ann McKillop; Frances Wang; Priya S Kishnani; David S Millington; Sarah P Young; Dora Il'yasova
Journal:  Ann Epidemiol       Date:  2012-10-11       Impact factor: 3.797

3.  Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial.

Authors:  Jill M Ellis; Hooi Kuan Tan; Ruth E Gilbert; David P R Muller; William Henley; Robert Moy; Rachel Pumphrey; Cornelius Ani; Sarah Davies; Vanessa Edwards; Heather Green; Alison Salt; Stuart Logan
Journal:  BMJ       Date:  2008-02-21

4.  Glucagon-Like Peptide-1 Cleavage Product Improves Cognitive Function in a Mouse Model of Down Syndrome.

Authors:  Stephen M Day; Wenzhong Yang; Xin Wang; Jennifer E Stern; Xueyan Zhou; Shannon L Macauley; Tao Ma
Journal:  eNeuro       Date:  2019-05-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.